Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and weight loss compared to GLP-1 receptor analogues (semaglutide, dulaglutide) in patients with type 2 diabetes.
For patients with Type 2 Diabetes seeking significant weight loss and glucose control, tirzepatide offers superior efficacy compared to existing GLP-1 analogues like semaglutide. It is administered as a once-weekly injection, starting at 5mg and titrating up to 15mg, combined with diet and exercise.
current studies show that the glucose lowering and weight loss effects of tirzepatide are at least as effective as GLP-1 RAs with a similar adverse effect profile. Some studies, though not conclusive, predict that tirzepatide may in fact be more potent than GLP-1 RAs at reducing weight.
Why this rating
Based on multiple Phase III randomized controlled trials (SURPASS series) with large sample sizes and statistically significant results.
Source
Beyond glycemia: Comparing tirzepatide to GLP-1 analogues
John Andraos et al. · Reviews in Endocrine and Metabolic Disorders · 2023
DOI 10.1007/s11154-023-09825-1
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →